Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...

In a report released yesterday, Robbie Marcus from J.P. Morgan maintained a Buy rating on Boston Scientific (BSX – Research Report), with a ...

Boston Scientific Co. (NYSE:BSX – Get Free Report) has been given an average recommendation of “Buy” by the twenty-three ...

Boston Scientific (NYSE:BSX – Free Report) had its price objective raised by Piper Sandler from $95.00 to $115.00 in a ...

Medical device maker Boston Scientific forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.

Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even ...

Raymond James analyst Jayson Bedford raised the firm’s price target on Boston Scientific (BSX) to $122 from $119 and keeps a Strong Buy rating ...

Boston Scientific said its fourth-quarter net income rose 12% amid robust demand for its stents, catheters and other cardiology devices. The Marlborough, Mass., medical-device maker posted ...

Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.

Boston Scientific Corporation ( NYSE: BSX) Q4 2024 Earnings Conference Call February 5, 2025 8:00 AM ET Jonathan Monson - SVP, IR Michael Mahoney - Chairman and CEO Daniel Brennan - EVP and CFO ...